What did @t.lund9x actually say?
The creator, who has multiple sclerosis, is documenting their first week of peptide injections. They describe intense burning and a visible welt at the injection site on nights three and four, and they adjusted their technique, switching from a 90-degree to a 45-degree angle and doubling their bacteriostatic water from 10 to 20 units. They close with the question most newcomers to peptide therapy are genuinely asking: "how long does it take for the effects to kick in?" and whether "skin is glowing and my bones aren't hurting" is a realistic payoff. This is not a promotional video. It reads as a genuine, somewhat frustrated diary entry from someone who is already comfortable with medical injections due to their MS treatment history and is now having a harder time than expected.
To their credit, they are not making wild cure claims. They are reporting what is happening to their body and asking for community feedback. That is a lower-risk format than the average peptide influencer, but it still warrants scrutiny.
Does the science back this up?
Injection site pain and welts are real, documented side effects of subcutaneous peptide administration, and the technique changes the creator describes are actually relevant to reducing them. But the expected benefits they are waiting for are far less evidence-based than the pain they are currently experiencing.
On the technique side, the switch to a 45-degree angle for subcutaneous injection is supported by nursing literature for leaner injection sites. A 90-degree angle is appropriate when there is sufficient subcutaneous fat. Doubling the bacteriostatic water reconstitution volume is a common community recommendation for reducing injection site irritation, and there is a logical pharmacological basis for it: lower concentration per milliliter means less localized osmotic stress on tissue.
On the benefit side, the claims floating around peptide communities about glowing skin and reduced bone pain are largely based on animal studies and small, often uncontrolled human trials. GHK-Cu, for example, has been studied for skin remodeling (Pickart et al., 2015, Journal of Aging Science), but human trial evidence for the dramatic cosmetic effects promoted on social media is thin. Bone pain relief from peptides like BPC-157 has shown promise in rodent models (Sikiric et al., 2018, Current Pharmaceutical Design), but translating that to a human MS patient is a stretch the research does not currently support.
What did they get wrong (or right)?
They got the technique adjustment right, and that is worth saying clearly. Increasing diluent volume and adjusting injection angle are both reasonable responses to injection site irritation. They are doing what a reasonably informed self-injector should do: observe, adjust, and reassess.
What they got wrong, or at least unsupported, is the implied expectation framework. The idea that peptide therapy will produce noticeable skin glow and bone pain relief within days is not grounded in any credible human trial data. The creator is essentially asking when they will feel results that have not been reliably demonstrated in their patient population at all. People with MS already navigate significant inflammatory and neurological pain; attributing changes in that symptom profile to a peptide without medical supervision is genuinely risky. It is not that peptides cannot have any effect. It is that without a controlled comparison and a prescribing clinician monitoring outcomes, the creator has no reliable way to know what they are actually experiencing.
There is also no mention of what specific peptide they are injecting, which matters enormously. "KLOW peptide" is not a recognized pharmaceutical or research compound name, which raises sourcing and purity questions that the creator does not address.
What should you actually know?
Injection site reactions like burning and welts are not automatically a sign something is wrong with the product, but they are a signal worth taking seriously, especially for someone with an autoimmune condition. MS involves immune dysregulation, and introducing a peptide compound without physician oversight in that context carries risks that are not well studied.
The reconstitution and injection angle adjustments the creator made are sensible harm-reduction steps, but they do not address the more important question of whether this peptide is appropriate for their medical situation at all. Anyone on disease-modifying therapy for MS should be having this conversation with their neurologist, not sourcing guidance from TikTok comment sections.
On the sourcing front: compounded or gray-market peptides vary significantly in purity and concentration. A 2021 analysis by Swissmedic found that a substantial proportion of peptide products purchased outside licensed pharmacy channels failed purity testing. What you reconstitute is only as safe as what is actually in the vial.
- Burning and welts at injection sites are common with subcutaneous peptide administration and can be reduced by increasing diluent volume or adjusting angle.
- No human trial evidence currently supports rapid cosmetic or bone pain benefits from peptide therapy in MS patients specifically.
- Gray-market peptide sourcing carries documented purity risks that are not resolved by careful injection technique.